<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Eplerenone: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Eplerenone: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Eplerenone: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="12423" href="/d/html/12423.html" rel="external">see "Eplerenone: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F165691"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Inspra</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52866742"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Inspra;</li>
<li>MINT-Eplerenone</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F165711"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antihypertensive;</li>
<li>
                        Diuretic, Potassium Sparing;</li>
<li>
                        Mineralocorticoid (Aldosterone) Receptor Antagonist</li></ul></div>
<div class="block doa drugH1Div" id="F165694"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="86fd017b-f098-427e-b843-c16a24638f11">Heart failure</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Heart failure:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> When initiating therapy, verify the following: serum potassium &lt;5 mEq/L <b>and </b>either serum creatinine ≤2.5 mg/dL in males and ≤2 mg/dL in females <b>or</b> eGFR &gt;30 mL/minute/1.73 m<sup>2</sup>. If patient develops hyperkalemia or kidney function worsens, reduce the dose, change to every-other-day dosing, or discontinue therapy; assess for other causes of hyperkalemia before permanent discontinuation. If serum potassium cannot be maintained &lt;5.5 mEq/L, discontinue therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33446410','lexi-content-ref-35363499']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33446410','lexi-content-ref-35363499'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Heart failure with preserved ejection fraction (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note:</b> For use in patients with symptomatic heart failure with preserved ejection fraction (HFpEF) (≥50%) who have an elevated serum natriuretic peptide level or have been hospitalized for heart failure in the last 12 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35363499']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35363499'])">Ref</a></span>). Some experts are more conservative regarding serum potassium for patients with HFpEF. They recommend initiating therapy or up-titrating the dose only if serum potassium is ≤4.7 mEq/L and eGFR is ≥30 mL/minute/1.73 m<sup>2</sup>. They recommend dose reduction or discontinuation if serum potassium is &gt;5 mEq/L (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Borlaug.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Borlaug.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Oral:</b> Initial: 25 mg once daily; may double the dose after 4 weeks if serum potassium and kidney function are stable, to a maximum target dose of 50 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35363499','lexi-content-ref-Borlaug.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35363499','lexi-content-ref-Borlaug.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Heart failure with reduced ejection fraction (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note: </b>Should be considered for use in patients with symptomatic (New York Heart Association class II to IV) heart failure with reduced ejection fraction (HFrEF) (≤40%) as part of an optimal medical regimen for HFrEF (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35363499']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35363499'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Oral:</b> Initial: 25 mg once daily; may double the dose after 4 weeks if serum potassium and kidney function are stable, to a maximum target dose of 50 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35363499','lexi-content-ref-21073363']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35363499','lexi-content-ref-21073363'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Post myocardial infarction, complicated by reduced ejection fraction:</b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note: </b>Should be considered for use following acute myocardial infarction in patients with left ventricular ejection fraction ≤40% plus symptoms of heart failure or diabetes. Use in addition to other pharmacologic therapies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35363499']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35363499'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Oral:</b> Initial: 25 mg once daily; may double the dose after 4 weeks if serum potassium and kidney function are stable, up to a maximum target dose of 50 mg once daily.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4f0c92d9-ad08-4643-a848-3296ddf5258e">Hypertension, chronic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypertension, chronic (alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Not recommended for initial management but may be considered as additional therapy for resistant hypertension in patients who do not respond adequately to combination therapy with preferred agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29133356','lexi-content-ref-29356711']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29133356','lexi-content-ref-29356711'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 50 mg once daily; evaluate response after ~2 to 4 weeks and titrate dose, as needed, to a maximum of 50 mg twice daily. Twice daily dosing is usually required for adequate BP lowering. Patients with severe asymptomatic hypertension and no signs of acute end organ damage should be evaluated for medication titration within 1 week (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29133356','lexi-content-ref-29356711','lexi-content-ref-Mann.2019a']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29133356','lexi-content-ref-29356711','lexi-content-ref-Mann.2019a'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2077fe7f-3b26-4f56-b690-0a9b9ad8a8ea">Primary aldosteronism</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Primary aldosteronism (alternative agent) (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 25 mg twice daily; gradually titrate to the lowest effective dose, up to 300 mg/day. For patients undergoing surgical intervention, administer the last dose of eplerenone on the day of surgery, then discontinue eplerenone on postoperative day 1 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26934393','lexi-content-ref-21451421']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26934393','lexi-content-ref-21451421'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991869"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Heart failure</b>:</p>
<p style="text-indent:-2em;margin-left:4em;">eGFR ≥50 mL/minute/1.73 m<sup>2</sup>: No initial dose adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">eGFR 31 to 49 mL/minute/1.73 m<sup>2</sup>: Initial: 25 mg every other day; may double the dose after 4 weeks if serum potassium and kidney function are stable, up to a maximum target dose of 25 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23741058']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23741058'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">eGFR ≤30 mL/minute/1.73 m<sup>2</sup>: Not recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23741058']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23741058'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis:</b> Not removed by hemodialysis.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypertension, chronic (alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≥50 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;50 mL/minute or serum creatinine &gt;2 mg/dL (males) or &gt;1.8 mg/dL (females): Use is contraindicated.</p></div>
<div class="block doha drugH1Div" id="F50989175"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. Systemic exposure is increased in moderate hepatic impairment (Child-Pugh class B).</p></div>
<div class="block doe drugH1Div" id="F165695"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block arsc drugH1Div" id="F56238144"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Hyperkalemia</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Eplerenone can cause reversible<b> hyperkalemia</b>; however, if potassium is monitored periodically and with suspected changes in electrolytes (vomiting, diarrhea), the risk does not appear to translate into a higher risk of hospitalization or death (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18824643']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18824643'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; related to the pharmacologic action. Competes with aldosterone for binding to the mineralocorticoid receptor, thereby inhibiting the exchange of sodium for potassium in the distal convoluted renal tubule and preventing potassium excretion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16200104']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16200104'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Intermediate; usually occurs within 4 weeks of initiation or dose titration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21214724']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21214724'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Doses &gt;100 mg daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16200104']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16200104'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older patients (≥75 years of age) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23810881']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23810881'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Diabetes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23810881']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23810881'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Kidney impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23810881']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23810881'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Excessive potassium intake (eg, potassium supplements, potassium-containing salt substitutes)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concomitant use of certain medications (eg, angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, sacubitril/valsartan, nonsteroidal anti-inflammatory drugs, moderate CYP3A inhibitors)</p>
<p style="text-indent:-2em;margin-left:6em;">• Baseline serum potassium &gt;4.3 mEq/L (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18824643']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18824643'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Prior use of antiarrhythmic agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18824643']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18824643'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Proteinuria</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F165661"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Endocrine &amp; metabolic: Hyperkalemia (cardiac failure, post-myocardial infarction: 3%; &gt;5.5 mEq/L: 16%; ≥6 mEq/L: 6%)<span class="lexi-table-link-container"> (<a aria-label="Hyperkalemia table link" class="lexi-table-link" data-table-id="lexi-content-hyperkalemia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-hyperkalemia')">table 1</a>)</span><span class="table-link" style="display:none;">Hyperkalemia</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Hyperkalemia" frame="border" id="lexi-content-hyperkalemia" rules="all">
<caption>
<b>Eplerenone: Adverse Reaction: Hyperkalemia</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Eplerenone)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Eplerenone)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">16%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">11%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Cardiac failure, post-myocardial infarction</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3251</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3237</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">&gt;5.5 mEq/L</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Cardiac failure, post-myocardial infarction</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3251</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3237</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">≥6 mEq/L</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Cardiac failure, post-myocardial infarction</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3307</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3301</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%: Renal: Increased serum creatinine (cardiac failure, post-myocardial infarction: 2% to 7%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Acute myocardial infarction, angina pectoris</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Gynecomastia, increased gamma-glutamyl transferase</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Abnormal vaginal hemorrhage</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness, headache</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Renal insufficiency</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Angioedema</p></div>
<div class="block coi drugH1Div" id="F165675"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Serum potassium &gt;5.5 mEq/L at initiation; CrCl ≤30 mL/minute; concomitant use of strong CYP3A4 inhibitors (eg, ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir).</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:4em;">The following additional contraindications apply to patients with hypertension: Type 2 diabetes mellitus with microalbuminuria; serum creatinine &gt;2.0 mg/dL in males or &gt;1.8 mg/dL in females; CrCl &lt;50 mL/minute; concomitant use with potassium supplements or potassium-sparing diuretics (eg, amiloride, spironolactone, triamterene).</p>
<p style="text-indent:-2em;margin-left:4em;">Based on the Endocrine Society (ES) clinical practice guidelines on the diagnosis and treatment of primary adrenal insufficiency, use of eplerenone in patients with Addison disease is contraindicated (ES [Bornstein 2016]).</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Hypersensitivity to eplerenone or any component of the formulation; serum potassium &gt;5 mEq/L at initiation; severe hepatic impairment (Child-Pugh class C); clinically significant hyperkalemia; concomitant use with potassium supplements or potassium-sparing diuretics</p>
<p style="text-indent:-2em;margin-left:4em;">The following additional contraindications apply to patients with hypertension: Serum creatinine &gt;1.5 mg/dL [132 micromole/L] in males or &gt;1.3 mg/dL [115 micromole/L] in females</p></div>
<div class="block war drugH1Div" id="F165659"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Heart failure: When evaluating a heart failure patient for eplerenone treatment, eGFR should be &gt;30 mL/minute/1.73 m<sup>2</sup> or creatinine should be ≤2.5 mg/dL (males) or ≤2 mg/dL (females) with no recent worsening and potassium should be &lt;5 mEq/L with no history of severe hyperkalemia. Discontinue therapy if serum potassium cannot be maintained &lt;5.5 mEq/L or if kidney function worsens. Consider the entire medical regimen and other potential causes of hyperkalemia (AHA/ACC/HFSA [Heidenreich 2022]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with moderate to severe hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Kidney impairment: Use with caution in patients with mild kidney impairment.</p></div>
<div class="block foc drugH1Div" id="F165669"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Inspra: 25 mg, 50 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 25 mg, 50 mg</p></div>
<div class="block geq drugH1Div" id="F165656"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F165677"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Eplerenone Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg (per each): $4.17 - $4.34</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $4.17 - $4.34</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Inspra Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg (per each): $16.90</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $16.90</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866743"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Inspra: 25 mg, 50 mg [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 25 mg, 50 mg</p></div>
<div class="block adm drugH1Div" id="F165672"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> Administer with or without food.</p></div>
<div class="block use drugH1Div" id="F165671"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypertension, chronic:</b> Management of hypertension. <b>Note: Not</b> recommended for the initial treatment of hypertension (ACC/AHA [Whelton 2018]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Post myocardial infarction, complicated by heart failure with reduced ejection fraction:</b> To improve survival of stable patients with symptomatic heart failure (left ventricular ejection fraction ≤40%) following acute myocardial infarction.</p></div>
<div class="block off-label drugH1Div" id="F25473681"><span class="drugH1">Use: Off-Label: Adult</span><p>Heart failure with preserved ejection fraction; Heart failure with reduced ejection fraction; Primary aldosteronism</p></div>
<div class="block mst drugH1Div" id="F165718"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Older Adult: High-Risk Medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Beers Criteria: Diuretics are identified in the Beers Criteria as potentially inappropriate medications to be used with caution in patients 65 years and older due to the potential to cause or exacerbate syndrome of inappropriate antidiuretic hormone secretion (SIADH) or hyponatremia; monitor sodium concentration closely when initiating or adjusting the dose in older adults (Beers Criteria [AGS 2023]).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Inspra may be confused with Spiriva</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F165705"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F165663"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When used at chemotherapy doses, hold blood pressure lowering medications for 24 hours before amifostine administration. If blood pressure lowering therapy cannot be held, do not administer amifostine. Use caution with radiotherapy doses of amifostine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ammonium Chloride: Potassium-Sparing Diuretics may enhance the adverse/toxic effect of Ammonium Chloride. Specifically the risk of systemic acidosis. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amphetamines: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Angiotensin II Receptor Blockers: Eplerenone may enhance the hyperkalemic effect of Angiotensin II Receptor Blockers. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Angiotensin-Converting Enzyme Inhibitors: Eplerenone may enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Arginine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brigatinib: May diminish the antihypertensive effect of Antihypertensive Agents. Brigatinib may enhance the bradycardic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May diminish the hypotensive effect of Blood Pressure Lowering Agents. Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): Potassium-Sparing Diuretics may enhance the hyperkalemic effect of CycloSPORINE (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of Eplerenone.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Eplerenone. Management: If coadministered with moderate CYP3A4 inhibitors, the max dose of eplerenone is 25 mg daily if used for heart failure; if used for hypertension initiate eplerenone 25 mg daily, titrate to max 25 mg twice daily.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Eplerenone.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Desmopressin: Hyponatremia-Associated Agents may enhance the hyponatremic effect of Desmopressin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dexmethylphenidate: May diminish the therapeutic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diacerein: May enhance the therapeutic effect of Diuretics. Specifically, the risk for dehydration or hypokalemia may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Drospirenone-Containing Products: May enhance the hyperkalemic effect of Potassium-Sparing Diuretics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Finerenone: Potassium-Sparing Diuretics may enhance the hyperkalemic effect of Finerenone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fludrocortisone: May diminish the therapeutic effect of Mineralocorticoid (Aldosterone) Receptor Antagonists. Mineralocorticoid (Aldosterone) Receptor Antagonists may diminish the therapeutic effect of Fludrocortisone.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunarizine: May enhance the therapeutic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Heparin: May enhance the hyperkalemic effect of Eplerenone.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Heparins (Low Molecular Weight): May enhance the hyperkalemic effect of Potassium-Sparing Diuretics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Increasing Effects: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Lowering Effects: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Indoramin: May enhance the hypotensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levodopa-Foslevodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa-Foslevodopa. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lithium: Potassium-Sparing Diuretics may increase the serum concentration of Lithium. Potassium-Sparing Diuretics may decrease the serum concentration of Lithium. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Loop Diuretics: May enhance the hypotensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methylphenidate: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicorandil: May enhance the hyperkalemic effect of Potassium-Sparing Diuretics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents: May diminish the antihypertensive effect of Eplerenone. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Eplerenone.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists: May enhance the adverse/toxic effect of Diuretics. Opioid Agonists may diminish the therapeutic effect of Diuretics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polyethylene Glycol-Electrolyte Solution: Diuretics may enhance the nephrotoxic effect of Polyethylene Glycol-Electrolyte Solution. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium Salts: Eplerenone may enhance the hyperkalemic effect of Potassium Salts.  Management: This combination is contraindicated in patients receiving eplerenone for treatment of hypertension. Potassium supplements may be needed to treat/prevent hypokalemia in select patients with heart failure receiving eplerenone and high dose loop diuretics.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium-Sparing Diuretics: May enhance the hyperkalemic effect of other Potassium-Sparing Diuretics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prazosin: Antihypertensive Agents may enhance the hypotensive effect of Prazosin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Silodosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Phosphates: Diuretics may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): Potassium-Sparing Diuretics may enhance the hyperkalemic effect of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Terazosin: Antihypertensive Agents may enhance the hypotensive effect of Terazosin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tolvaptan: May enhance the hyperkalemic effect of Potassium-Sparing Diuretics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trimethoprim: May enhance the hyperkalemic effect of Eplerenone.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Urapidil: Antihypertensive Agents may enhance the hypotensive effect of Urapidil. <i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F165688"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Grapefruit juice increases eplerenone AUC ~25%. Management: Dosage adjustments of eplerenone may be needed. </p></div>
<div class="block rep_considerations drugH1Div" id="F57000401"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Eplerenone may be preferred for the treatment of primary aldosteronism (PA) in patients who are planning to become pregnant and require treatment with a mineralocorticoid receptor antagonist (Forestiero 2022; Riester 2015). Use of eplerenone may be considered for patients experiencing menstrual irregularities or erectile dysfunction with other mineralocorticoid receptor antagonists during treatment for PA or resistant hypertension (ACC/AHA [Whelton 2018]; ES [Funder 2016]; Kallistratos 2018).</p>
<p style="text-indent:0em;margin-top:2em;">Medications considered acceptable for the treatment of chronic hypertension during pregnancy may generally be continued in patients trying to conceive. The use of mineralocorticoid receptor antagonists is not recommended for the treatment of chronic hypertension in pregnant patients (ACOG 2019). Consider transitioning to an agent preferred for use during pregnancy in patients planning to become pregnant (ACC/AHA [Whelton 2018]; ACOG 2019; NICE 2019).</p>
<p style="text-indent:0em;margin-top:2em;">Patients with heart failure who are planning to become pregnant should discontinue mineralocorticoid receptor antagonists prior to conception (AHA/ACC/HFSA [Heidenreich 2022]).</p></div>
<div class="block pri drugH1Div" id="F165678"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Eplerenone crosses the placenta (Saito 2021).</p>
<p style="text-indent:0em;margin-top:2em;">Data related to eplerenone use in pregnancy are limited (Cabassi 2012; Gehlert 2021; Gunganah 2015; Hutter 2006; Morton 2011; Morton 2017).</p>
<p style="text-indent:0em;margin-top:2em;">Chronic maternal hypertension is associated with adverse events in the fetus/infant. Chronic maternal hypertension may increase the risk of birth defects, low birth weight, premature delivery, stillbirth, and neonatal death. Actual fetal/neonatal risks may be related to the duration and severity of maternal hypertension. Untreated chronic hypertension may also increase the risks of adverse maternal outcomes, including gestational diabetes, preeclampsia, delivery complications, stroke, and myocardial infarction (ACOG 2019). Patients with preexisting hypertension may continue their medication during pregnancy unless contraindications exist (ESC [Regitz-Zagrosek 2018]). When treatment of chronic hypertension during pregnancy is indicated, the use of mineralocorticoid receptor antagonists is generally not recommended (ACOG 2019).</p>
<p style="text-indent:0em;margin-top:2em;">Data specific to the treatment of primary aldosteronism (PA) in pregnancy are limited. Patients with PA should stop eplerenone before conception if possible. If treatment is stopped and PA is not controlled, eplerenone can be restarted in the second or third trimester (ES [Funder 2016]; Forestiero 2022; Riester 2015; Sanga 2022).</p>
<p style="text-indent:0em;margin-top:2em;">Heart failure in pregnancy is associated with adverse maternal and fetal outcomes, including premature birth, infants born small for gestational age, and increased risk of maternal and fetal death (Bright 2021). When treatment of heart failure during pregnancy is needed, the use of an agent other than a mineralocorticoid receptor antagonist is recommended (AHA/ACC/HFSA [Heidenreich 2022]; ESC [Regitz-Zagrosek 2018]).</p>
<p style="text-indent:0em;margin-top:2em;">Case reports describe the use of potassium sparing diuretics such as eplerenone for the adjunctive treatment of Gitleman syndrome during pregnancy (Calò 2012; Moustakakis 2012; Shahzad 2019).</p></div>
<div class="block brc drugH1Div" id="F20617100"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Eplerenone is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Data related to the presence of eplerenone in breast milk are available from a case report. Eplerenone 50 mg once daily was initiated during pregnancy and continued postpartum. Multiple breast milk samples were obtained on postpartum days 7 and 35. The highest breast milk concentration observed was 161.2 ng/mL, obtained 4 hours after the dose on postpartum day 35. Using a milk concentration of 161.2 ng/mL, authors of the study calculated the estimated daily infant dose via breast milk to be 0.024 mg/kg/day, providing a relative infant dose of 3% based on the weight adjusted maternal dose. The infant was partially breastfed (over 50%); no adverse reactions were reported, and normal development was observed at 1 and 3 months (Saito 2021).</p></div>
<div class="block dic drugH1Div" id="F165679"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Do not use salt substitutes containing potassium.</p></div>
<div class="block mop drugH1Div" id="F165667"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">BP; serum potassium (prior to therapy, within the first week, 1 month after start of treatment or dose adjustment, then periodically as clinically indicated); serum potassium and serum creatinine within 3 to 7 days after initiating concurrent therapy with a moderate CYP3A inhibitor, angiotensin-converting enzyme (ACE) inhibitor, angiotensin-II receptor blocker (ARB), or nonsteroidal anti-inflammatory drug.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Heart failure:</b> Serum potassium and kidney function should be checked in 3 days after initiation, at 1 week after initiation, at least monthly for the first 3 months of therapy, and every 3 months thereafter. If adding or increasing the dose of concomitant ACE inhibitors or ARBs, a new cycle of monitoring should be done. If serum potassium increases to &gt;5.5 mEq/L or kidney function worsens, hold doses until potassium is &lt;5 mEq/L and consider restarting with a reduced dose after confirming resolution of hyperkalemia/kidney insufficiency for at least 72 hours. If serum potassium cannot be maintained &lt;5.5 mEq/L, discontinue therapy (ACC [Maddox 2021]; AHA/ACC/HFSA [Heidenreich 2022]).</p></div>
<div class="block pha drugH1Div" id="F165658"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Aldosterone, a mineralocorticoid, increases blood pressure primarily by inducing sodium and water retention. Overexpression of aldosterone is thought to contribute to myocardial fibrosis (especially following myocardial infarction) and vascular fibrosis. Mineralocorticoid receptors are located in the kidney, heart, blood vessels, and brain. Eplerenone selectively blocks mineralocorticoid receptors reducing blood pressure in a dose-dependent manner and appears to prevent myocardial and vascular fibrosis.</p></div>
<div class="block phk drugH1Div" id="F165674"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: V<sub>d</sub>: 42 to 90 L </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein binding: ~50%; primarily to alpha<sub>1</sub>-acid glycoproteins </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Primarily hepatic via CYP3A4; metabolites inactive </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Bioavailability: 69%</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: ~3 to 6 hours </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak, plasma: ~1.5 to 2 hours; may take up to 4 weeks for full antihypertensive effect </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Urine (~67%); feces (~32%); &lt;5% as unchanged drug in urine and feces</p></div>
<div class="block phksp drugH1Div" id="F51154045"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: AUC and C<sub>max</sub> increased 38% and 24%, respectively, in severe kidney impairment and decreased by 26% and 3%, respectively, in hemodialysis.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: C<sub>max</sub> and AUC increased 3.6% and 42%, respectively, in moderate hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">Older adult: C<sub>max</sub> and AUC increased 22% and 45%, respectively.</p>
<p style="text-indent:-2em;margin-left:2em;">Race/ethnicity: C<sub>max</sub> and AUC decreased 19% and 25%, respectively, in black patients.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F5539853"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Eptus | Inspra</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Aldactone EP | Dilacor | Eplena | Eplerona | Etiles</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Eplerenon accord | Eplerenon actavis | Eplerenon Generic | Eplerenon hcs | Eplerenon pharmathen | Eplerenon ratiopharm | Eplerenon stada | Inspra</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Apo eplerenone | Eplerenone an | Espler | Inpler | Inspra</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Aldonist | Epleron</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Eplerenone ab | Eplerenone mylan | Inspra</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Carditrust | Eplerenone accord | Eplerium | Espiro | Inspra</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Eplerenon mepha | Eplerenon sandoz | Eplerenon spirig hc | Inspra</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Amiocar | Inspra</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Cardionona | Epnone | Inspra</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Apleria | Eplerenon actavis | Eplerenon sandoz | Inspra</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Epleraxiro | Epleren.rati | Eplerenhexal | Eplerenon 1a pharma | Eplerenon aaa pharma | Eplerenon accord | Eplerenon al | Eplerenon beta | Eplerenon heumann | Eplerenon mylan | Eplerenon puren | Eplerenon stada | Eplerenon tillomed | Eplerenon vivanta | Eplerenon zentiva | Inspra</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Inspra</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Apleria | Eplerenone accord | Inspra</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Aldospira | Carfalone | Cholaflux | Eplorefix | Tensopleron</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Eplerenona Actavis | Eplerenona amneal | Eplerenona Apotex | Eplerenona bluefish | Eplerenona Cinfa | Eplerenona Combix | Eplerenona Kern pharma | Eplerenona krka | Eplerenona lorien | Eplerenona mabo | Eplerenona Mylan | Eplerenona Normon | Eplerenona pensa | Eplerenona Ranbaxy | Eplerenona Ratiopharm | Eplerenona Sandoz | Eplerenona Stada | Eplerenona Tarbis | Eplerenona tecnigen | Eplerenona teva | Eplerenona vir | Eplerenona Zentiva | Inspra</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Eplehef</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Inspra</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Eplerenone accord | Eplerenone arrow | Eplerenone biogaran | Eplerenone cristers | Eplerenone Dci | Eplerenone eg | Eplerenone krka | Eplerenone mylan | Eplerenone sandoz | Eplerenone teva | Eplerenone zentiva | Eplerenone Zydus | Inspra</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Inspra</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Eleveon | Eplerenone/teva | Eplerium | Evadil | Inosamin | Inspra | Licepler | Vaner</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Diuron | Inspra</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Eplerenon krka | Eplerenone mylan | Inspra | Licepler</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Eplerenone actavis | Eplerenone bluefish | Eplerenone krka | Eplerenone mylan | Eplerenone rowex | Inspra</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Inspra</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Eplebless | Eplecard | Eplehef | Epleran | Eplerite | Eplinice | Epnone | Eptus | Exenta | Exinia | Ezuric | Planep</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Eplerenone accord | Eplerenone doc generici | Eplerenone krka | Eplerenone mylan | Eplerenone tecnigen | Inspra</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Elerax | Epnone | Inspra</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Selara</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Eplone | Epnone | Inspra</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Eprenone</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Inspra</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Eplerenone arrow | Eplerenone biogaran</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Apleria | Inspra</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Inspra</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Eplerenone accord | Inspra | Plecard</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Inspra</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Inspra | Inspra ic | Zinfarel</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Dosterep</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Eplerenon accord | Eplerenon aurobindo | Eplerenon cf | Eplerenon krka | Eplerenon mylan | Eplerenon sandoz | Eplerenon teva | Inspra</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Eplerenon accord | Eplerenon krka | Inspra</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Inspra</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Inspra</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Cardise | Epler | Epliron</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Eleveon | Eplenocard | Eplerenon medical valley | Espiro | Inspra | Malidum | Nonpres</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Inspra</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Eplerenona | Eplerenona bluepharma | Inspra</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Eplerone | Hidroretic</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Inspra</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Inspra</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Eplenor | Eplerenon teva | Espiro | Ipleron</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Eplerenon accord | Eplerenon actavis | Eplerenon bluefish | Eplerenon krka | Eplerenon medical valley | Eplerenon stada | Eplerenone sandoz | Eplerenone teva | Inspra</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Inspra</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Carditrust | Elreptic | Enplerasa | Eplerenon stada | Inspra</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Aldepla | Apleria | Eleveon | Eplerad | Eplerenon mylan | Eplerenon sandoz | Eplerenon stada | Eplerenone actavis | Eplerenone teva | Inspra</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Inspra</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Epleday</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Epnone | Inspra</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Dekriz | Efez | Eplepres | Epletor | Espiro | Renial</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Epnone</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Inspra | Suficard</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eplerenone-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30575676">
<a name="30575676"></a>American College of Obstetricians and Gynecologists (ACOG). ACOG Practice Bulletin No. 203: Chronic hypertension in pregnancy. <i>Obstet Gynecol</i>. 2019;133(1):e26-e50.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eplerenone-drug-information/abstract-text/30575676/pubmed" id="30575676" target="_blank">30575676</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25260718">
<a name="25260718"></a>Amsterdam EA, Wenger NK, Brindis RG, et al; American College of Cardiology; American Heart Association Task Force on Practice Guidelines; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons; American Association for Clinical Chemistry. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [published correction appears in <i>J Am Coll Cardiol</i>. 2014;64(24):2713-2714]. <i>J Am Coll Cardiol</i>. 2014;64(24):e139-e228. doi: 10.1016/j.jacc.2014.09.017.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eplerenone-drug-information/abstract-text/25260718/pubmed" id="25260718" target="_blank">25260718</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29356711">
<a name="29356711"></a>Bazoukis G, Thomopoulos C, Tsioufis C. Effect of mineralocorticoid antagonists on blood pressure lowering: overview and meta-analysis of randomized controlled trials in hypertension.<i> J Hypertens</i>. 2018;36(5):987-994. doi: 10.1097/HJH.0000000000001671.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eplerenone-drug-information/abstract-text/29356711/pubmed" id="29356711" target="_blank">29356711</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26760044">
<a name="26760044"></a>Bornstein SR, Allolio B, Arlt W, et al. Diagnosis and treatment of primary adrenal insufficiency: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2016;101(2):364-389.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eplerenone-drug-information/abstract-text/26760044/pubmed" id="26760044" target="_blank">26760044</a>]</span>
<span class="doi">10.1210/jc.2015-1710</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Borlaug.1">
<a name="Borlaug.1"></a>Borlaug BA, Colucci WS. Treatment and prognosis of heart failure with preserved ejection fraction. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 10, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34259013">
<a name="34259013"></a>Bright RA, Lima FV, Avila C, Butler J, Stergiopoulos K. Maternal Heart Failure. <i>J Am Heart Assoc</i>. 2021;10(14):e021019. doi:10.1161/JAHA.121.021019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eplerenone-drug-information/abstract-text/34259013/pubmed" id="34259013" target="_blank">34259013</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22146514">
<a name="22146514"></a>Cabassi A, Rocco R, Berretta R, et al. Eplerenone use in primary aldosteronism during pregnancy. <i>Hypertension.</i> 2012;59(2):e18-e19.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eplerenone-drug-information/abstract-text/22146514/pubmed" id="22146514" target="_blank">22146514</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21999963">
<a name="21999963"></a>Calò LA, Caielli P. Gitelman's syndrome and pregnancy: new potential pathophysiological influencing factors, therapeutic approach and materno-fetal outcome. <i>J Matern Fetal Neonatal Med.</i> 2012;25(8):1511-1513. doi:10.3109/14767058.2011.629254<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eplerenone-drug-information/abstract-text/21999963/pubmed" id="21999963" target="_blank">21999963</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16200104">
<a name="16200104"></a>Craft J. Eplerenone (Inspra), a new aldosterone antagonist for the treatment of systemic hypertension and heart failure. <i>Proc (Bayl Univ Med Cent)</i>. 2004;17(2):217-220. doi:10.1080/08998280.2004.11927973<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eplerenone-drug-information/abstract-text/16200104/pubmed" id="16200104" target="_blank">16200104</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23810881">
<a name="23810881"></a>Eschalier R, McMurray JJ, Swedberg K, et al. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure). <i>J Am Coll Cardiol</i>. 2013;62(17):1585-1593. doi:10.1016/j.jacc.2013.04.086<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eplerenone-drug-information/abstract-text/23810881/pubmed" id="23810881" target="_blank">23810881</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35536535">
<a name="35536535"></a>Forestiero V, Sconfienza E, Mulatero P, Monticone S. Primary aldosteronism in pregnancy. <i>Rev Endocr Metab Disord.</i> Published online May 10, 2022. doi:10.1007/s11154-022-09729-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eplerenone-drug-information/abstract-text/35536535/pubmed" id="35536535" target="_blank">35536535</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26934393">
<a name="26934393"></a>Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2016;101(5):1889-1916. doi: 10.1210/jc.2015-4061.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eplerenone-drug-information/abstract-text/26934393/pubmed" id="26934393" target="_blank">26934393</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33995571">
<a name="33995571"></a>Gehlert J, Morton A. Eplerenone as a treatment for resistant hypertension in pregnancy. <i>Obstet Med.</i> 2021;14(1):35-38. doi:10.1177/1753495X19825967<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eplerenone-drug-information/abstract-text/33995571/pubmed" id="33995571" target="_blank">33995571</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24243703">
<a name="24243703"></a>Go AS, Bauman M, King SM, et al. An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention [published online November 15, 2013]. <i>Hypertension</i>.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eplerenone-drug-information/abstract-text/24243703/pubmed" id="24243703" target="_blank">24243703</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26783442">
<a name="26783442"></a>Gunganah K, Carpenter R, Drake WM. Eplerenone use in primary aldosteronism during pregnancy. <i>Clin Case Rep</i>. 2015;4(1):81-82. doi: 10.1002/ccr3.355.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eplerenone-drug-information/abstract-text/26783442/pubmed" id="26783442" target="_blank">26783442</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35363499">
<a name="35363499"></a>Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. <i>Circulation</i>. 2022;145(18):e895-e1032. doi:10.1161/CIR.0000000000001063<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eplerenone-drug-information/abstract-text/35363499/pubmed" id="35363499" target="_blank">35363499</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16760705">
<a name="16760705"></a>Hutter DA, Berkowitz R, Davis SE 3rd, Ashtyani H. Application of continuous positive airway pressure in hypoxemic acute respiratory failure associated with diastolic dysfunction in pregnancy. <i>Congest Heart Fail</i>. 2006;12(3):174-175.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eplerenone-drug-information/abstract-text/16760705/pubmed" id="16760705" target="_blank">16760705</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pfizer.1">
<a name="Pfizer.1"></a>Inspra (eplerenone) [prescribing information]. New York, NY: Pfizer Inc; October 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Upjohn.1">
<a name="Upjohn.1"></a>Inspra (eplerenone) [product monograph]. Etobicoke, Ontario, Canada: Upjohn Canada ULC; July 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24352797">
<a name="24352797"></a>James PA, Oparil S, Carter BL, et al. 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults: Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8). <i>JAMA</i>. 2014;311(5):507-520.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eplerenone-drug-information/abstract-text/24352797/pubmed" id="24352797" target="_blank">24352797</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30799782">
<a name="30799782"></a>Kallistratos MS, Pittaras A, Theodoulidis I, Grassos C, Poulimenos LE, Manolis AJ. Adverse effects of mineralocorticoid receptor antagonist administration. <i>Curr Pharm Des</i>. 2018;24(46):5537-5541. doi:10.2174/1381612825666190222144359<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eplerenone-drug-information/abstract-text/30799782/pubmed" id="30799782" target="_blank">30799782</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20610207">
<a name="20610207"></a>Lindenfeld J, Albert NM, Boehmer JP, et al. HFSA 2010 Comprehensive Heart Failure Practice Guideline. <i>J Card Fail.</i> 2010;16(6):e1-e194.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eplerenone-drug-information/abstract-text/20610207/pubmed" id="20610207" target="_blank">20610207</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33446410">
<a name="33446410"></a>Maddox TM, Januzzi JL Jr, Allen LA, et al. 2021 update to the 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction: a report of the American College of Cardiology Solution Set Oversight Committee. <i>J Am Coll Cardiol</i>. 2021;77(6):772-810. doi:10.1016/j.jacc.2020.11.022<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eplerenone-drug-information/abstract-text/33446410/pubmed" id="33446410" target="_blank">33446410</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mann.2019a">
<a name="Mann.2019a"></a>Mann JFE, Flack JM. Choice of drug therapy in primary (essential) hypertension. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 7, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28279449">
<a name="28279449"></a>Morton A, Laurie J. Eplerenone in the management of resistant hypertension with obstructive sleep apnoea in pregnancy. <i>Pregnancy Hypertens</i>. 2017;7:54-55.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eplerenone-drug-information/abstract-text/28279449/pubmed" id="28279449" target="_blank">28279449</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21342329">
<a name="21342329"></a>Morton A, Panitz B, Bush A. Eplerenone for Gitelman Syndrome in Pregnancy. <i>Nephrology (Carlton).</i> 2011;16(3):349.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eplerenone-drug-information/abstract-text/21342329/pubmed" id="21342329" target="_blank">21342329</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26064481">
<a name="26064481"></a>Moustakakis MN, Bockorny M. Gitelman syndrome and pregnancy.<i> Clin Kidney J</i>. 2012;5(6):552-555. doi:10.1093/ckj/sfs126<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eplerenone-drug-information/abstract-text/26064481/pubmed" id="26064481" target="_blank">26064481</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12468576">
<a name="12468576"></a>Mulatero P, Rabbia F, Milan A, et al. Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism. <i>Hypertension</i>. 2002;40(6):897-902. doi: 10.1161/01.hyp.0000038478.59760.41<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eplerenone-drug-information/abstract-text/12468576/pubmed" id="12468576" target="_blank">12468576</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.1">
<a name="NICE.1"></a>National Institute for Health and Care Excellence (NICE). Hypertension in pregnancy: diagnosis and management. www.nice.org.uk/guidance/ng133. Published June 25, 2019. Accessed December 1, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24589852">
<a name="24589852"></a>Nishimura RA, Otto CM, Bonow RO, et al, 2014 AHA/ACC guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2014;129(23):2440-92. doi: 10.1161/CIR.0000000000000029.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eplerenone-drug-information/abstract-text/24589852/pubmed" id="24589852" target="_blank">24589852</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23247304">
<a name="23247304"></a>O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines [published correction appears in <i>Circulation</i>. 2013;128(25):e481]. <i>Circulation</i>. 2013;127(4):e362-e425.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eplerenone-drug-information/abstract-text/23247304/pubmed" id="23247304" target="_blank">23247304</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21451421">
<a name="21451421"></a>Parthasarathy HK, Ménard J, White WB, et al. A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism. <i>J Hypertens</i>. 2011;29(5):980-990. doi: 10.1097/HJH.0b013e3283455ca5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eplerenone-drug-information/abstract-text/21451421/pubmed" id="21451421" target="_blank">21451421</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18824643">
<a name="18824643"></a>Pitt B, Bakris G, Ruilope LM, DiCarlo L, Mukherjee R; EPHESUS Investigators. Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). <i>Circulation</i>. 2008 Oct 14;118(16):1643-50. doi:10.1161/CIRCULATIONAHA.108.778811<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eplerenone-drug-information/abstract-text/18824643/pubmed" id="18824643" target="_blank">18824643</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12668699">
<a name="12668699"></a>Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. <i>N Engl J Med.</i> 2003;348(14):1309-1321.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eplerenone-drug-information/abstract-text/12668699/pubmed" id="12668699" target="_blank">12668699</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10471456">
<a name="10471456"></a>Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. <i>N Engl J Med.</i> 1999;341(10):709-717.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eplerenone-drug-information/abstract-text/10471456/pubmed" id="10471456" target="_blank">10471456</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30165544">
<a name="30165544"></a>Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al. 2018 ESC guidelines for the management of cardiovascular diseases during pregnancy. <i>Eur Heart J</i>. 2018;39(34):3165-3241.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eplerenone-drug-information/abstract-text/30165544/pubmed" id="30165544" target="_blank">30165544</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25163723">
<a name="25163723"></a>Riester A, Reincke M. Progress in primary aldosteronism: mineralocorticoid receptor antagonists and management of primary aldosteronism in pregnancy. <i>Eur J Endocrinol</i>. 2015;172(1):R23-R30. doi:10.1530/EJE-14-0444<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eplerenone-drug-information/abstract-text/25163723/pubmed" id="25163723" target="_blank">25163723</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33564177">
<a name="33564177"></a>Saito J, Mito A, Yakuwa N, et al. Eplerenone levels in maternal serum, cord blood, and breast milk during pregnancy and lactation. <i>Hypertens Res</i>. 2021;44(7):879-881. doi:10.1038/s41440-021-00621-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eplerenone-drug-information/abstract-text/33564177/pubmed" id="33564177" target="_blank">33564177</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35686552">
<a name="35686552"></a>Sanga V, Rossitto G, Seccia TM, Rossi GP. Management and outcomes of primary aldosteronism in pregnancy: a systematic review. <i>Hypertension</i>. 2022:101161HYPERTENSIONAHA12118858. doi:10.1161/HYPERTENSIONAHA.121.18858<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eplerenone-drug-information/abstract-text/35686552/pubmed" id="35686552" target="_blank">35686552</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30867665">
<a name="30867665"></a>Shahzad MA, Mukhtar M, Ahmed A, Ullah W, Saeed R, Hamid M. Gitelman syndrome: a rare cause of seizure disorder and a systematic review. <i>Case Rep Med.</i> 2019;2019:4204907. doi:10.1155/2019/4204907<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eplerenone-drug-information/abstract-text/30867665/pubmed" id="30867665" target="_blank">30867665</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21214724">
<a name="21214724"></a>Sica DA, Flack JM. Treatment considerations with aldosterone receptor antagonists. <i>J Clin Hypertens (Greenwich)</i>. 2011;13(1):65-69. doi:10.1111/j.1751-7176.2010.00377.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eplerenone-drug-information/abstract-text/21214724/pubmed" id="21214724" target="_blank">21214724</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22052934">
<a name="22052934"></a>Smith SC Jr, Benjamin EJ, Bonow RO, et al. AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update: A Guideline From the American Heart Association and American College of Cardiology Foundation. <i>Circulation.</i> 2011;124(22):2458-2473.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eplerenone-drug-information/abstract-text/22052934/pubmed" id="22052934" target="_blank">22052934</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24341872">
<a name="24341872"></a>Weber MA, Schiffrin EL, White WB, et al. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. <i>J Clin Hypertens (Greenwich)</i>. 2014;16(1):14-26. doi: 10.1111/jch.12237.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eplerenone-drug-information/abstract-text/24341872/pubmed" id="24341872" target="_blank">24341872</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29133356">
<a name="29133356"></a>Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines [published correction appears in <i>Hypertension</i>. 2018;71(6):e140-e144]. <i>Hypertension</i>. 2018;71(6):e13-e115. doi: 10.1161/HYP.0000000000000065<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eplerenone-drug-information/abstract-text/29133356/pubmed" id="29133356" target="_blank">29133356</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23741058">
<a name="23741058"></a>Yancy CW, Jessup M, Bozkurt B, et al; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. <i>Circulation</i>. 2013;128(16):e240-e327.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eplerenone-drug-information/abstract-text/23741058/pubmed" id="23741058" target="_blank">23741058</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21073363">
<a name="21073363"></a>Zannad F, McMurray JJ, Krum H, et al; EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. <i>N Engl J Med</i>. 2011;364(1):11-21. doi: 10.1056/NEJMoa1009492.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eplerenone-drug-information/abstract-text/21073363/pubmed" id="21073363" target="_blank">21073363</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 8789 Version 390.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
